Drugs / APHD-012
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05803772 | Mar 2023 → Feb 2024 | glucose intolerance, prediabetes syndrome | Aphaia Pharma US LLC | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT07008456 Comparator | Sep 2025 → Jul 2026 overdue | morbid obesity | Aphaia Pharma US LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT05385978 Comparator | Nov 2022 → Nov 2024 overdue | obesity disorder | Aphaia Pharma US LLC | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APHD 012 | “dextrose beads formulations (APHD 012 and APHD 002) combined with a gel composition” NCT07008456 ↗ |